Sotalol is a methane sulfonanilide beta adrenergic antagonist used to treat life-threatening ventricular arrhythmias and to maintain sinus rhythm in atrial fibrillation or flutter. Sotalol is a methanesulfonanilide developed in 1960.
- Mechanism
- Curator reviewed · 5 references
Sotalol inhibits beta-1 adrenoceptors in the myocardium as well as rapid potassium channels to slow repolarization, lengthen the QT interval, and slow and shorten conduction of action potentials through the atria. The action of sotalol on beta adrenergic receptors lengthens the sinus node cycle, conduction time through the atrioventricular node, refractory period, and duration of action potentials.
- Primary indication
- Sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter.Curator reviewed · 2 structured indications
- Formula / weight
- C12H20N2O3S · 272.364 g/mol (avg)
- First approval
- Canada, 1996 · United States, 1992
- Code names
- MJ 1999
- Brand names
Resolves to
ZBMZVLHSJCTVON-UHFFFAOYSA-NSMILESCC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Sotalol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account